Testolactone
| Clinical data | |
|---|---|
| Trade names | Teslac |
| Other names | 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid δ-lactone; SQ-9538; Fludestrin; NSC-12173; NSC-23759 |
| AHFS/Drugs.com | Consumer Drug Information |
| Routes of administration | By mouth |
| Drug class | Aromatase inhibitor; Antiestrogen |
| ATC code |
|
| Pharmacokinetic data | |
| Protein binding | ~85% |
| Metabolism | Liver |
| Excretion | Urine |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.012.304 |
| Chemical and physical data | |
| Formula | C19H24O3 |
| Molar mass | 300.398 g·mol−1 |
| 3D model (JSmol) | |
| |
| (what is this?) (verify) | |
Testolactone (INN, USAN) (brand name Teslac) is a non-selective, irreversible, steroidal aromatase inhibitor which is used as an antineoplastic drug to treat advanced-stage breast cancer. The drug was discontinued in 2008 and is no longer available for medical use.